Interview with Neurescue CEO Habib Frost: Aortic Occlusion That Promotes Blood Flow to the Brain and Heart

NeurescueNEURESCUE System, a Danish-based medical technology company, is a balloon catheter designed to occlude the aorta, significantly increasing blood flow to the heart and brain. This mechanism is intended to provide emergency treatment for patients suffering from bleeding or cardiac arrest.

Both bleeding and cardiac arrest represent unmet needs, with significant deaths each year. Currently, only 1 in 10 survives cardiac arrest, demonstrating the severe consequences of this patient population.

Aortic occlusion helps control blood loss and increases blood flow to the heart and brain, so this procedure helps to save time for patients suffering from bleeding or cardiac arrest. The device is delivered via the femoral artery and a safety feedback system helps ensure that the device is properly placed during temporary balloon inflating. Inflation itself is regulated to prevent excessive inflation and rupture.

Med Gadget I had the opportunity to talk with Habib Frost, Founder and CEO of Neurescue, about technology and what it means for the consequences of cardiac arrest.

Conn Hastings, Medgadget: What is the overview of bleeding and cardiac arrest and how they affect patients?

Habib Frost, Neu Rescue: Cardiac arrest is the sudden loss of a person’s heart rate and is a major health problem that accounts for an estimated 15-20% of all deaths. In the United States, more than 500,000 people die of cardiac arrest each year, and only one in ten people experience cardiac arrest outside the hospital and survive until discharge. If the event occurs in a hospital setting, the number is not very high and the survival rate reaches about 25%. Cardiac arrest is the leading cause of years of loss in heart disease. 40-50% of all life lost in heart disease is due to cardiac arrest.

Bleeding is severe bleeding caused by car accidents, gunshot wounds, pregnancy-related bleeding, etc. Accidents are the leading cause of death for individuals under the age of 45, and bleeding accounts for one-third of these deaths. In the United States, 60,000 people die each year as a result of annual bleeding, with an estimated 1.9 million deaths worldwide each year, of which 1.5 million are due to trauma.

Medgadget: How are these conditions currently being treated? Why is this not optimal?

Habib Frost: The current standard treatment for cardiac arrest is cardiopulmonary resuscitation (CPR) with chest compressions and defibrillation. Today’s CPR replaces only 35% of blood flow to the heart and brain. This is not high enough to resuscitate the majority of patients and does not provide enough time to successfully bridge most patients to advanced curative treatment.

In the case of bleeding, such as ongoing or severe internal bleeding due to trauma, surgery is usually required to correct the problem. If internal bleeding is severe, emergency surgery should be performed within minutes. The survival rate for torso bleeding that cannot be externally compressed is only 45%. This is because the individual usually bleeds before the final surgical treatment.

Medgadget: What made you decide to develop this technology?

Habib Frost: As a final year medical student, I witnessed a young girl suffering from cardiac arrest. Despite the availability of all available treatments, the team of doctors failed to save her life. Later that day, the team was called into another case of cardiac arrest. This time I was a woman in her thirties. Once again, they couldn’t save her life. I felt devastated and at that moment I wanted to help improve standard treatment for patients with cardiac arrest.

Medgadget: Please give us an overview of NEURESCUE devices and how they work.

Habib Frost: The NEURESCUE device is the world’s first intelligent balloon catheter for aortic occlusion. This is an emergency technique that supercharges blood flow to the heart and brain within 1 minute of deployment. The catheter-based device is delivered through the femoral artery and temporarily inflates a soft balloon in the aorta to direct blood flow to the upper body. This procedure is performed to control blood loss, increase perfusion to the heart and brain, and bridge patients to additional life-saving treatment options. Increased blood flow to the heart and brain through temporary aortic occlusion increases the chances of immediate resuscitation and at the same time opens up new opportunities to bridge the patient to final treatment.

The NEURESCUE device consists of a catheter and a control unit that houses patented sensor guidance and auto-expansion technology. The device’s intelligent safety feedback system assists in catheter positioning and regulates balloon pressure to monitor blood pressure while preventing hyperinflation, rupture, and tissue damage. When deployed, the device supercharges blood flow to the heart and brain within a minute. Its simple design is optimized for emergencies, and the device’s automatic expansion and sensor guidance allow the procedure to be safely performed with or without a fluoroscopy. This will provide access to first aid not only at the bedside of the ER and ICU, but also outside the hospital.

This is a video with details of the NEURE SCUE device and a demo in use.

Medgadget: How does this device help improve patient outcomes in bleeding and cardiac arrest?

Habib Frost:
NEURESCUE devices increase blood flow to the heart and brain, increasing the chances of immediate resuscitation. It also enables new opportunities to connect patients to final treatment. NEURESCUE devices complement existing standard treatments for cardiac arrest and bleeding. This device may bridge patients for definitive treatment options such as cardiopulmonary mechanical therapy (ECMO), stents (PCI), cardiac support devices (LVAD), implantable pacemakers or defibrillators. .. In the case of bleeding, the device buys an important time for the final surgical treatment.

The patented device helps ensure safe positioning and swelling during CPR or bleeding when the fluoroscopy is barely available. This enables emergency treatment in the ER, ICU, bedside, and out of the hospital.

Medgadget: Congratulations to the FDA for approving the application for exemption from clinical trial devices. This paves the way for clinical trials of the device in the treatment of cardiac arrest. When, where, and how do you plan to conduct the test, and if the test results are positive, what does that mean for technology and patients with cardiac arrest?

Habib Frost: We are very much looking forward to starting patient enrollment in US clinical trials later this year. This can lead to expanded indications for NEURESCUE devices as an aid to refractory cardiac arrest. When looking at the low survival rates of individuals undergoing CPR, it is imperative that new therapies be fully considered. There has been little improvement in the outcome of cardiac arrest over the last few decades and we are aiming for our technology to change this.

Link: Neurescue homepage …

Flashback: Neurescue’s new device can save those suffering from the major murders of U.S. citizens Interview with Neurescue CEO Habib Frost: Aortic Occlusion That Promotes Blood Flow to the Brain and Heart

Back to top button